Evidence map›Paper›PMID 39269120›Full record

ReviewNanomaterials (Basel, Switzerland)2024

Recent Progress on Covalent Organic Frameworks Supporting Metal Nanoparticles as Promising Materials for Nitrophenol Reduction.

Mohammad Dinari, Zaynab Golshadi, Parvin Asadi, Amie E Norton, Katelyn R Reid, Benson Karimi

Abstract readReview
In one paragraph

Review in Nanomaterials (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mohammad DinariDepartment of Chemistry, Isfahan University of Technology, Isfahan 84156-83111, Iran.ORCID 0000-0001-5291-7142
Zaynab GolshadiDepartment of Chemistry, Isfahan University of Technology, Isfahan 84156-83111, Iran.
Parvin AsadiDepartment of Medicinal Chemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan 81746-73461, Iran.
Amie E NortonDepartment of Entomology, Kansas State University, 123 W Waters Hall, 1603 Old Claflin Place, Manhattan, KS 66503, USA.
Katelyn R ReidDepartment of Physical and Environmental Sciences, Texas A&M University Corpus Christi, Corpus Christi, TX 78412, USA.
Benson KarimiDepartment of Physical and Environmental Sciences, Texas A&M University Corpus Christi, Corpus Christi, TX 78412, USA.ORCID 0000-0002-0815-187X

Funding

Welch Foundation BT 0041
6 · The paper itself

Abstract

With the utilization of nitrophenols in manufacturing various materials and the expansion of industry, nitrophenols have emerged as water pollutants that pose significant risks to both humans and the environment. Therefore, it is imperative to convert nitrophenols into aminophenols, which are less toxic. This conversion process is achieved through the use of noble metal nanoparticles, such as gold, silver, copper, and palladium. The primary challenge with noble metal nanoparticles lies in their accumulation and deactivation, leading to a decrease in catalyst activity. Covalent organic frameworks (COFs) are materials characterized by a crystalline structure, good stability, and high porosity with active sites. These properties make them ideal substrates for noble metal nanoparticles, enhancing catalytic activity. This overview explores various articles that focus on the synthesis of catalysts containing noble metal nanoparticles attached to COFs as substrates to reduce nitrophenols to aminophenols.

Indexed as

aminophenolcovalent organic frameworksheterogeneous catalystnitrophenol reductionnoble metal nanoparticles

Identifiers

PMID39269120
PMCPMC11397240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.